A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03719326 |
|
Recruitment Status :
Completed
First Posted : October 25, 2018
Last Update Posted : December 27, 2022
|
Sponsor:
Arcus Biosciences, Inc.
Collaborator:
Infinity Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Arcus Biosciences, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | July 1, 2021 |
| Actual Study Completion Date : | July 2, 2021 |